Jazz Pharmaceuticals (JAZZ) Tops Q3 EPS by 51c; Lifts Revenue Outlook
Tweet
Share
E-mail
Get Alerts JAZZ Hot Sheet
Price: $237.72 --0%
Revenue Growth %: +6.2%
Financial Fact:
Research and development: 47.8M
Today's EPS Names:
DTGI, CRMT, STZ, More
Revenue Growth %: +6.2%
Financial Fact:
Research and development: 47.8M
Today's EPS Names:
DTGI, CRMT, STZ, More
Join SI Premium – FREE
Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q3 EPS of $5.17, $0.51 better than the analyst estimate of $4.66. Revenue for the quarter came in at $940.65 million versus the consensus estimate of $939.97 million.
GUIDANCE:
Jazz Pharmaceuticals raises FY2022 revenue midpoint to $3.65 billion, versus the consensus of $3.65 billion.
For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Concentrix Corporation (CNXC) Misses Q2 EPS by 1c; Guides lower than expectations
- Raymond James Starts Mid Penn Bancorp (MPB) at Outperform
- Goldman Sachs Reinstates Kokusai Electric Corp (6525:JP) at Neutral
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
